Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sumanirole · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| sumanirole | DRUG | - |
| ropinirole | DRUG | - |
Inclusion Criteria: Idiopathic Parkinson's disease \< 7 years duration Modified Hoehn and Yahr Scale Stages I through III Age greater than or equal to 30 years old Patients or their partners must use adequate contraceptive methods Patients who are willing and able to comply with scheduled visit...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
Sumanirole is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for the treatment of Parkinson disease. It was studied in Phase 3 clinical trials for the signs and symptoms of early Parkinson disease. Sumanirole has not been approved and remains an investigational therapy in clinical development.
Sumanirole was developed to treat the signs and symptoms of early Parkinson disease. Two Phase 3 studies evaluated it in adults aged 30 years and older with early Parkinson disease, enrolling a combined 1,454 participants. Sumanirole is investigational and is not an approved treatment for Parkinson disease.
Sumanirole targets DRD2, the dopamine D2 receptor, and acts as an agonist at that receptor. This DRD2 agonist activity is the basis for its development in Parkinson disease, where dopamine signaling is impaired. Sumanirole is a small molecule and remains an investigational agent.
Sumanirole is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 3 clinical program evaluating sumanirole in early Parkinson disease. The drug remains investigational and has not been approved for any indication.
Sumanirole reached Phase 3 clinical development for Parkinson disease. Both Phase 3 trials have been completed, and no trials are currently active. Sumanirole is investigational and is not FDA approved; it has not completed regulatory review for marketing authorization.
Sumanirole was studied in two completed Phase 3 trials: NCT00058838, which enrolled 854 participants across the United States, Argentina, Australia, Austria, Belgium, Colombia, France, Germany, Greece, Italy, Mexico, Peru, Puerto Rico, and Spain, and NCT00036218, which enrolled 600 participants in the United States, Argentina, Mexico, and Puerto Rico. Both evaluated early Parkinson disease.